Incyte Corporation INCY

INCY Company Overview

Incyte Corporation (NASDAQ: INCY) is a U.S.-based biopharmaceutical company focused on the discovery, development, and commercialization of proprietary therapeutics, primarily in oncology, hematology, inflammation, and autoimmune diseases. The company operates within the biotechnology and specialty pharmaceuticals industries and generates revenue through marketed medicines, collaborative agreements, milestone payments, and royalties. Its largest revenue driver has historically been Jakafi (ruxolitinib), a Janus kinase (JAK) inhibitor approved in the United States for myelofibrosis, polycythemia vera, and graft-versus-host disease. Incyte has also expanded into dermatology and solid tumors through products such as Opzelura and Pemazyre.

The company serves physicians, hospitals, specialty pharmacies, and healthcare systems primarily in the United States, Europe, and parts of Asia. Incyte’s strategic positioning is built around its expertise in targeted therapies and immunology-focused drug development, particularly JAK pathway science. Founded in 1991 in Palo Alto, California, the company initially focused on genomics and bioinformatics before transitioning into therapeutics development. Over time, it evolved into a fully integrated biopharmaceutical company with internal research, clinical development, manufacturing oversight, and commercial operations.